Multicentric study of beclomethasone dipropionate nasal aerosol in adults with seasonal allergic rhinitis |
| |
| Authors: | Sheldon C. Siegel Roger M. Katz Gary S. Rachelefsky Bernard D. Geller Leonard L. Montag Milan L. Brandon Stanley J. Cannon |
| |
| Affiliation: | 1. From the Allergy Medical Clinic and the Allergy and Clinical Immunology Medical Group, Los Angeles, Calif., USA;2. From the Allergy Medical Group of San Diego, San Diego, Calif., USA;3. From the South Miami Ear, Nose and Throat Associates, Miami, Fla., USA |
| |
| Abstract: | A double-blind, parallel-design multicentric study, in two phases, was conducted to examine the safety and efficacy of 2-wk treatment with various doses of beclomethasone dipropionate nasal aerosol (BDNA) and placebo in adults with seasonal allergic rhinitis. In phase I, 162 patients received BDNA, 33.5 μg/burst (o.d., b.i.d., t.i.d., q.i.d.), or placebo; in phase II, 189 patients received BDNA 42, μg/burst (b.i.d., q.i.d.), or placebo. In both phases, statistically significant (p < 0.05) differences favoring BDNA over placebo were found for all efficacy measures (global evaluation and total and individual symptom scores). In phase I, response to treatment increased as BDNA dosage increased, with a leveling off at t.i.d. dosage. In both phases, marked improvements were seen by week 1, with maximum improvement during week 2. Eighty-seven patients had adverse reactions—sneezing and nasal burning were most common. No suppression in morning cortisol levels was seen, nor were Candida infections promoted. A 2-wk treatment with BDNA was safe and effective in the treatment of seasonal allergic rhinitis in adults. |
| |
| Keywords: | BDNA Beclomethasone dipropionate nasal aerosol |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
